title: [Treatment approaches for bronchopulmonary infection in myasthenia gravis patients].
abstract: Nineteen patients with bronchopulmonary infection and myasthenia gravis were enrolled in the study. The microbiological analysis of the specimens of phlegm and bronchial secretion revealed both grampositive and gramnegative bacteria. All the isolates were susceptible to the antibiotic used (cefoperazone/sulbactam). Intravenous immunoglobulins (IvIgs) were used to increase the treatment efficacy, to opsonize the infection foci and to decrease the hospitalization terms. The antibiotic therapy and simultaneous use of intravenous immunoglobulins provided higher clinical efficacy in 16 out of 19 patients (84.2%).
authors: V I
authors: VI
authors: Sokolova
authors: A G
authors: AG
authors: Sanadze
authors: D A
authors: DA
authors: Sychev
authors: M B
authors: MB
authors: Babarina
authors: D A
authors: DA
authors: Zaĭkov
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001996:Bronchopneumonia / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D002438:Cefoperazone / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000254:growth & development; D006094:Gram-Positive Bacteria / Q000187:drug effects / Q000254:growth & development; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D018410:Pneumonia, Bacterial / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D013407:Sulbactam / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D016756:Immunoglobulins, Intravenous; D002438:Cefoperazone; D013407:Sulbactam